Details for Patent: 8,410,131

Which drugs does patent 8,410,131 protect, and when does it expire?

Patent 8,410,131 protects AFINITOR and is included in one NDA.

Protection for AFINITOR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and eighty-one patent family members in twenty-eight countries.

Summary for Patent: 8,410,131

Title:	Cancer treatment
Abstract:	Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.
Inventor(s):	Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood
Assignee:	Novartis Pharmaceuticals Corp
Application Number:	US10/468,520
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,410,131
Patent Claim Types: see list of patent claims	Use; Delivery; Dosage form;

Drugs Protected by US Patent 8,410,131

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010	AB	RX	Yes	No					Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	AB	RX	Yes	Yes					Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-004	Mar 30, 2012	AB	RX	Yes	No					Y

International Family Members for US Patent 8,410,131

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2269603		CA 2015 00058	Denmark
European Patent Office	2269603		300769	Netherlands
European Patent Office	2269603		122015000094	Germany